Abstract

Provided are compositions and methods for use in the treatment of tinnitus or a symptom thereof in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising cannabidiol (CBD), cannabidiolic acid (CBDA) or a combination thereof; and a mixture of at least three selected terpenes.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/01 - Hydrocarbons
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 27/16 - Otologicals

Abstract

A composition comprising at least one terpene for use in modulation of a physiological function via at least one selected from the group consisting of agonism of a cannabinoid type 1 receptor (CB1R), modulation of agonism of a CB1R, modulation of antagonism of a CB1R, agonism of a cannabinoid type 2 receptor (CB2R), modulation of agonism of a CB2R, modulation of antagonism of a CB2R and combinations thereof; and methods of use thereof.

IPC Classes  ?

• A61K 31/01 - Hydrocarbons
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

Provided is a method for treating a condition related to cannabinoid type 1 (CB1) receptor activation by administering a composition comprising at least one terpene, optionally together with tetrahydrocannabinol (THC). Further provided is a method for treating a condition related to Transient Receptor Potential Cation Channel, subfamily A, member 1 (TRPA1) receptor activation by administering a composition comprising at least one terpene selected from the group consisting of linalool, menthol, eucalyptol, terpincol, citral and combinations thereof, optionally together with tetrahydrocannabinol (THC). Further provided is a method for treating a condition related to Transient Receptor Potential Cation Channel, subfamily V, member 1 (TRPA1) receptor activation by administering a composition comprising at least one terpene selected from the group consisting of citral, caryophyllene and combinations thereof, optionally together with cannabidiol (CBD).

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

Provided are pharmaceutical compositions comprising at least one cannabinoid, at least one non-cannabinoid, non-terpene compound, such as an active pharmaceutical ingredient (API) or a nutraceutical and a pharmaceutically acceptable carrier and uses thereof in therapy, such as in treatment of a neurodevelopmental disorder, a neurodegenerative disorder or acute pain in a subject.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/05 - Phenols

Abstract

Provided is a method for producing an acid of a target cannabinoid acid (RCOOH), comprising providing an aqueous solution comprising a salt (RCOOM) of the target cannabinoid and at least one impurity at a first total target cannabinoid content of salt to impurity wt/wt ratio; selectively removing at least a portion of the at least one impurity from the aqueous solution to form a refined aqueous solution with a second total target cannabinoid content of the salt to impurity ratio, wherein the second ratio is greater than the first ratio; reducing a pH of the refined aqueous solution to a pH of less than 6, to form an organic phase comprising the target cannabinoid acid (RCOOH) and a residual aqueous phase, wherein R is the target cannabinoid and M is a counter ion.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/01 - Hydrocarbons
• A61K 36/19 - Acanthaceae (Acanthus family)
• C07C 51/02 - Preparation of carboxylic acids or their salts, halides, or anhydrides from salts of carboxylic acids
• C07C 51/42 - SeparationPurificationStabilisationUse of additives
• C07C 51/48 - SeparationPurificationStabilisationUse of additives by liquid-liquid treatment
• B01D 11/02 - Solvent extraction of solids
• B02C 23/20 - Adding fluid, other than for crushing or disintegrating by fluid energy after crushing or disintegrating

Abstract

A method for treating a plant comprising applying a composition comprising at least three active agents selected from the group consisting of carvacrol, thymol, 4-terpineol, alpha-terpinene, alpha-pinene, beta-pinene, d-limonene, azadirachtin, salannin, beta-caryophyllene, menthol, menthone, beta-cymene, 1,8-cineole, verbenone, and cannabidiol (CBD) to at least a portion of the plant.

IPC Classes  ?

• A01N 31/16 - Oxygen or sulfur directly attached to an aromatic ring system with two or more oxygen or sulfur atoms directly attached to the same aromatic ring system
• A01N 25/04 - Dispersions or gels
• A01N 27/00 - Biocides, pest repellants or attractants, or plant growth regulators containing hydrocarbons
• A01N 39/00 - Biocides, pest repellants or attractants, or plant growth regulators containing aryloxy- or arylthio-aliphatic or cycloaliphatic compounds, containing the group or , e.g. phenoxyethylamine, phenylthio-acetonitrile, phenoxyacetone
• A01P 3/00 - Fungicides
• A01P 7/04 - Insecticides
• A01P 13/02 - HerbicidesAlgicides selective

Abstract

Provided are printable compositions comprising a cannabinoid and cannabis wax, products comprising such compositions and a substrate, methods for the production thereof and methods of use thereof in providing an accurately reproducible dose of a cannabinoid to a subject. Further provided is a product comprising a smokable substrate and at least one composition comprising at least one cannabinoid.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 9/70 - Web, sheet or filament bases
• B41J 2/01 - Ink jet

Abstract

Preventing an occurrence of a condition or symptom thereof arising due to exposure to a stressful event, by administering to a subject in need thereof a therapeutically effective amount of a composition comprising at least one cannabinoid, at least one terpene selected from the group consisting of Pinene, Myrcene, Caryophyllene, Humulene, Nerolidol, Bisabolol, Linalool, Fenchol, Limonene, Terpinene, Terpineol, Eucalyptol, Geraniol, Borneol, Sabinene, Ocimene and combinations thereof, where the at least one terpene is present in the composition at a concentration of at least about 20 wt %, based on the weight of the total amount of terpenes in the composition and at least 5% by weight of a non-cannabinoid, non-terpene carrier.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Provided are methods for treating a bladder condition in a subject in need thereof by administering to said subject a therapeutically effective dose of a composition comprising at least one cannabinoid and a carrier. Also provided are cannabinoid composition comprising at least one cannabinoid, a carrier and at least one drug selected from the group consisting of an anticholinergic drug and an adrenergic drug and uses of such compositions for treating a bladder condition.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A composition of at least one cannabinoid, at least one terpene of pinene, limonene, linalool, caryophyllene, myrcene, humulene, terpineol, nerolidol, bisabolol, geraniol, borneol, eucalyptol in a concentration of at least about 20 wt % of terpenes in the composition, or at least two terpenes in a combined amount of at least about 40 wt % of terpenes in the composition, at least 5% by weight of a non-cannabinoid, non-terpene carrier, less than 5% by weight glycol, and less than 20% by weight water, and where the non-cannabinoid, non-terpene carrier comprises a) at least 5% by weight cellulose and the total terpenes to total cannabinoids weight/weight ratio in the composition is from 0.1 to 1.0, or b) less than 5% by weight cellulose and the total terpenes to total cannabinoids weight/weight ratio is from 0.05 to 1.0, obtained by providing and blending the cannabinoid and terpene in amounts configured to provide the ratio.

IPC Classes  ?

• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/01 - Hydrocarbons
• A61K 31/05 - Phenols
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 11/06 - Antiasthmatics
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
• A61P 35/00 - Antineoplastic agents

Abstract

Provided is a composition comprising an ester derived from at least one acid form of a cannabinoid (such as one selected from the group consisting of cannabigerolic acid (CBGA), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabichromenic acid (CBCA), cannabigerovarinic acid (CBGVA), tetrahydrocanabivarinic acid (CBCVA), cannabidivarinic acid (CBDVA) and cannabichromevarinic acid (CBCVA) and combinations thereof) and a water-soluble alkanol and uses thereof in therapy.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol

Abstract

Provided is a method for sterilizing an initial plant material wherein the plant material is contaminated with at least one species of yeast and/or mold to a total yeast and mold count greater than 1x103 colony forming units (CFU) per gram, the method comprising introducing the plant material into at least one closable receptacle; providing in the at least one closable receptacle a relative humidity within a range of between about 70% about 100%; and applying heat to the receptacle for a duration of between about 0.5 minutes and about 60 minutes, while maintaining the relative humidity within the range for at least a portion of the duration, to provide sterilized plant material.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A23L 3/00 - Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
• A23L 3/005 - Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by heating using irradiation or electric treatment
• A23L 3/3445 - Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of gases, e.g. fumigation; Compositions or apparatus therefor in a controlled atmosphere comprising other gases in addition to CO2, N2, O2 or H2O
• A23B 7/005 - Preserving by heating
• A23B 7/01 - Preserving by heating by irradiation or electric treatment
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

Abstract

Provided is at least one terpene for use in modulation of a physiological function via modulation of activation of a Transient Receptor Potential (TRP) channel receptor, wherein the TRP is a member of subfamily A (TRPA) and the terpene is selected from the group consisting of linalool, menthol, eucalyptol, terpineol, citral and combinations thereof, and/or wherein the TRP is a member of subfamily V (TRPV) and the terpene is selected from the group consisting of citral, caryophyllene and combinations thereof. and methods of modulating a physiological function via modulation of activation of a TRP receptor in a subject, the method comprising administering to the subject at least one terpene.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61P 23/00 - Anaesthetics
• A61P 25/00 - Drugs for disorders of the nervous system

IPC Classes  ?

• A61K 31/05 - Phenols
• A61P 25/20 - HypnoticsSedatives
• A61P 25/24 - Antidepressants

Abstract

Provided are compositions comprising terpene mixtures consisting of 1000-4500 ppm myrcene, 1000-4000 ppm terpineol, 1000-5500 ppm caryophyllene and 1000-45000 ppm nerolidol; 1000-4500 ppm alpha-pinene, 1000-4000 ppm sabinene, 1000-4000 ppm limonene, 500-4000 ppm borneol and 1000-4500 ppm caryophyllene; 1000-4500 ppm alpha-pinene, 1000-4000 ppm linalool, 1000-4000 ppm terpineol, 1000-4000 ppm borneol, 1000-4500 ppm caryophyllene and 1000-4000 ppm nerolidol; 1000-4000 ppm myrcene, 500-5000 ppm linalool, 1000-4500 ppm caryophyllene and 500-4500 ppm nerolidol; or 1000-5500 ppm alpha-pinene, 1000-4000 ppm limonene, 500-4000 ppm linalool and 1000-4500 ppm caryophyllene, and uses in therapy.

IPC Classes  ?

• A61K 31/05 - Phenols
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61P 25/20 - HypnoticsSedatives
• A61P 25/24 - Antidepressants

Abstract

Provided is a cannabis-containing cigarette comprising a hollow elongated body having a proximal portion having an outer end configured for insertion into the mouth of a user, and a distal portion having an outer end configured to be lit. A cannabis material comprising a cannabinoid at a concentration of at least 5wt%; and a second smokable material comprising less than 2wt% cannabinoids are contained within the hollow elongated body. The cannabis material is present within the proximal portion of the hollow elongated body at a concentration of at least 35wt% of the total content of material within the proximal portion. The second material is present within the distal portion of the hollow elongated body at a concentration at least 70wt% of the total content of material within the distal portion. The length of the proximal portion is at least 2 times the length of the distal portion.

IPC Classes  ?

• A24B 15/167 - Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
• A24C 5/02 - Cigarette-filling machines
• A24D 1/02 - CigarsCigarettes with special covers
• A24D 1/18 - Selection of materials, other than tobacco, suitable for smoking
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61M 15/00 - Inhalators
• A61M 15/06 - Inhaling appliances shaped like cigars, cigarettes or pipes
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is a method for the production of a low-THC cannabinoid isolate, the method comprising providing an initial composition comprising at least one cannabinoid comprising THC and at least one target cannabinoid, partially separating THC from the target cannabinoid, to produce a first THC-enriched composition and a first THC- depleted composition; selectively oxidizing at least 30% of the THC in the first THC- enriched composition to form a first oxidized composition comprising at least one oxidation product of THC, residual THC, and said target cannabinoid; at least partially recovering the target cannabinoid; and combining first THC-depleted composition with the target cannabinoid recovered from the first oxidized composition.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Provided are methods for drying and sterilizing cannabis plant material comprising providing feed cannabis plant material having a water content of M0, wherein M0 is greater than 45%; partially drying the feed cannabis plant material to form a partially dried cannabis plant material having a water content of M1, wherein M1 is in the range of between 12% wt and 40% wt; sterilizing the partially dried cannabis plant material to form sterilized partially dried cannabis plant material having a water content of M3; and when said M3 is less than 8% wt or greater than 16% wt, adjusting said M3 to provide a water content of M2, wherein said M2 is between 8% wt and 16% wt. Further provided are methods and systems for drying of cannabis plant material.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A24B 15/18 - Treatment of tobacco products or tobacco substitutes
• A24B 15/22 - Treatment of tobacco products or tobacco substitutes by application of electric or wave energy or particle radiation

Abstract

Provided is a composition comprising at least one terpene for use in modulation of a physiological function via at least one selected from the group consisting of agonism of a cannabinoid type 1 receptor (CB1R), modulation of agonism of a CB1R, modulation of antagonism of a CB1R and combinations thereof; and methods of use thereof..

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

Homogeneous cannabis plant material compositions comprising tetrahydrocannabinol (THC) and cannabidiol (CBD) at specified concentrations, where the plant material is in the form of comminuted particles, where at least 70 wt % of the comminuted cannabis plant material is of a size greater than 0.3 and less than 4.2 millimeters, and where the composition comprises at least 1 wt % and less than 20 wt % moisture. Further provided are products comprising the compositions and methods of preparation thereof.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/05 - Phenols

Abstract

Provided is a method for producing at least one cannabinoid, the method comprising providing a cell capable of producing and secreting at least one cannabinoid; providing an organic solvent or an anion exchanger; growing the cell in a growth vessel in an aqueous fermentation medium comprising a carbon source, whereby the cell produces and secretes the at least one cannabinoid; contacting the cannabinoid-comprising fermentation medium with the organic solvent or the anion-exchanger, forming a cannabinoid-comprising organic solvent or a cannabinoid-carrying anion exchanger and a cannabinoid-depleted fermentation medium; and separating the cannabinoid- comprising organic solvent or the cannabinoid-carrying anion exchanger from the cannabinoid-depleted fermentation medium.

IPC Classes  ?

• C12N 1/16 - YeastsCulture media therefor
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07C 37/50 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions decreasing the number of carbon atoms
• C07C 51/42 - SeparationPurificationStabilisationUse of additives
• C07D 301/32 - SeparationPurification
• C07D 311/86 - Oxygen atoms, e.g. xanthones

Abstract

Provided is a composition comprising at least one carrier comprising a nanoporous material; and at least one cannabinoid and at least one non-cannabinoid, non-terpene impurity, wherein a concentration of carrier is between about 30wt% and about 90wt% of the total composition; a concentration of the cannabinoid is between about 10wt% and about 70wt% of the total composition; a combined concentration of the cannabinoid and the carrier is at least about 80wt% of the total composition; at least about 90wt% of the cannabinoid is adsorbed on the carrier; a ratio between a total weight of the cannabinoid and a total weight of the at least one impurity is at least about 1.5:1; and the carrier comprises discrete particles. Further provided are methods of preparation and methods of use of the composition..

IPC Classes  ?

• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/14 - Particulate form, e.g. powders

Abstract

Provided is a composition comprising at least one carrier comprising a nanoporous material; and at least one cannabinoid and at least one non-cannabinoid, non-terpene impurity, wherein a concentration of carrier is between about 30wt% and about 90wt% of the total composition; a concentration of the cannabinoid is between about 10wt% and about 70wt% of the total composition; a combined concentration of the cannabinoid and the carrier is at least about 80wt% of the total composition; at least about 90wt% of the cannabinoid is adsorbed on the carrier; a ratio between a total weight of the cannabinoid and a total weight of the at least one impurity is at least about 1.5:1; and the carrier comprises discrete particles. Further provided are methods of preparation and methods of use of the composition.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin

Abstract

Provided is a composition comprising (a) at least 50%wt carbohydrate, (b) less than 35%wt water (c) water activity in the range between 0.65 and 0.9, (d) at least one cannabinoid at a concentration of at least 0.1%wt of said composition; (e) a thickener, wherein the composition comprises less than 2%wt fat. Further provided are food products comprising the composition..

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof
• A21D 13/00 - Finished or partly finished bakery products

Abstract

Provided is a composition comprising multiple cannabis storage cavities and/or multiple cannabis secretory cells, wherein at least 20% of said storage cavities and/or at least 20% of said secretory cells are intact and wherein each of said intact storage cavities and/or each of said intact secretory cells contains therein at least one cannabinoid. Further provided are products comprising the composition and methods of use thereof.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61K 9/00 - Medicinal preparations characterised by special physical form
• B01D 11/00 - Solvent extraction

Abstract

Provided is a composition comprising a carrier and at least one of a terpene and a cannabinoid, wherein the carrier comprises discrete particles at 30°C; wherein the carrier comprises 50%wt to 99.9%wt of the total composition; wherein at least one of the terpene and the cannabinoid is carried on the carrier; wherein a total weight of the terpene and the cannabinoid forms 0.1%wt to 50%wt of the total composition; wherein the discrete particles each have a dimension in the range between 0.2mm and 5mm; and wherein at least 70% of the discrete particles each carry between 0.1mg and 100mg of the at least one of a terpene and a cannabinoid per particle.

IPC Classes  ?

• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/14 - Particulate form, e.g. powders

Abstract

Provided are compositions and methods for use in the treatment of tinnitus or a symptom thereof in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising cannabidiol (CBD), cannabidiolic acid (CBDA) or a combination thereof; and a mixture of at least three selected terpenes.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/01 - Hydrocarbons
• A61K 31/05 - Phenols
• A61K 31/015 - Hydrocarbons carbocyclic

Abstract

A composition of at least one cannabinoid in a specific amount, and at least one primary terpene in a specific amount, where a total terpenes to total cannabinoids weight/weight ratio in the composition is from about 0.05 to about 1.0.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 36/185 - Magnoliopsida (dicotyledons)

Abstract

A therapeutic product comprising at least one cannabinoid, at least one primary terpene, and at least 5% by weight of a non-cannabinoid, non-terpene carrier, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said product is about 0.1 to about 1.0; a method of treating certain conditions and/or symptoms in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a product comprising at least one primary terpene; a therapeutic product comprising a primary terpene blend, wherein said primary terpene blend comprises five or less terpenes, and wherein each one of those terpenes, where present, independently comprises at least 10% of the total terpene content.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/05 - Phenols
• A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts

Abstract

Provided is a method for treating a plant comprising applying a composition comprising at least three active agents selected from the group consisting of carvacrol, thymol, 4-terpineol, alpha-terpinene, alpha-pinene, beta-pinene, d-limonene, azadirachtin, salannin, beta-caryophyllene, menthol, menthone, beta-cymene, 1,8-cineole, verbenone, and cannabidiol (CBD) to at least a portion of the plant.

IPC Classes  ?

• A01N 43/14 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings
• A01N 53/00 - Biocides, pest repellants or attractants, or plant growth regulators containing cyclopropane carboxylic acids or derivatives thereof
• A01N 61/00 - Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
• A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests
• A01N 25/04 - Dispersions or gels
• A01N 25/08 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents

Abstract

Provided is a method for treating a condition related to cannabinoid type 1 (CB1) receptor activation by administering a composition comprising at least one terpene, optionally together with tetrahydrocannabinol (THC). Further provided is a method for treating a condition related to Transient Receptor Potential Cation Channel, subfamily A, member 1 (TRPA1) receptor activation by administering a composition comprising at least one terpene selected from the group consisting of linalool, menthol, eucalyptol, terpineol, citral and combinations thereof, optionally together with tetrahydrocannabinol (THC). Further provided is a method for treating a condition related to Transient Receptor Potential Cation Channel, subfamily V, member 1 (TRPA1) receptor activation by administering a composition comprising at least one terpene selected from the group consisting of citral, caryophyllene and combinations thereof, optionally together with cannabidiol (CBD).

IPC Classes  ?

• A61K 31/05 - Phenols
• A61K 31/01 - Hydrocarbons
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 23/00 - Anaesthetics
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

A method of treating a condition and/or a symptom associated with an effect of at least one element of the endocannabinoid system in an animal, the method including administering to the animal (i) a therapeutically effective amount of at least one microorganism and/or of a prebiotic thereof, where the microorganism is capable of modulating an effect of at least one element of the endocannabinoid system of the animal and (ii) a therapeutically effective amount of at least one compound capable of modulating an effect of at least one element of the endocannabinoid system of the animal. Further provided are compositions for use in such methods.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

Provided is a method for the production of at least two cannabis products, at least one of which is a smokable cannabis product, the method comprising: providing first and a second cannabis plant materials, each comprising attached trichomes comprising at least one cannabinoid at a concentration of about 0.5%wt to 25%wt of said respective cannabis plant material; mechanically treating said first cannabis plant material to separate 35%wt to 85%wt of trichomes to obtain separated trichomes and first trichome-depleted cannabis plant material; processing at least a fraction of said first separated trichomes into a first cannabis product; blending at least a fraction of said first trichome-depleted cannabis plant material with at least a fraction of said second cannabis plant material to form a blend, and processing said blend into a second product which is a smokable cannabis product comprising trichomes of each of said first and second cannabis plant materials.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/01 - Hydrocarbons
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 36/19 - Acanthaceae (Acanthus family)
• B01D 11/02 - Solvent extraction of solids
• B01D 29/56 - Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups Filtering elements therefor with multiple filtering elements, characterised by their mutual disposition in series connection
• B02C 23/20 - Adding fluid, other than for crushing or disintegrating by fluid energy after crushing or disintegrating

Abstract

Provided are pharmaceutical compositions comprising a pharmaceutically effective amount of a steroid and a pharmaceutically effective amount of at least one modulator selected from the group consisting of a transient receptor potential (TRP) channel modulator and a proliferatior-activated receptor (PRP) modulator, wherein cannabidiol is not present as the sole modulator, and uses thereof for treating a condition or a symptom thereof, wherein said condition involves inflammation, an immune disease, an autoimmune disease or a combination thereof.

IPC Classes  ?

• A61K 31/05 - Phenols
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

Provided is a liquid cannabis composition comprising CBD and/or CBDA at a concentration in the range of from about 26wt% to about 50wt%; at least two mono- terpenes selected from the group consisting of alpha-Pinene, beta-Pinene, Myrcene, Ocimene, Terpinolene, Limonene, Sabinene, Linalool, Carene, Eucalyptol, Terpineol, Geraniol, Borneol, Terpinene, Camphene, Fenchol and combinations thereof; and a carrier, wherein a ratio between a total weight of said mono-terpenes and a total weight of CBD and CBDA is in the range of from about 0.02 to about 0.2. Also provided are methods of use thereof in the treatment of epilepsy and/or an autism spectrum disorder.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Provided is a pharmaceutical composition for treating a microbial imbalance, the composition comprising a pharmaceutically effective amount of at least one strain of probiotic bacteria, a pharmaceutically effective amount of cannabidiol and a pharmaceutically acceptable excipient. Further provided are feminine hygiene products comprising the composition and methods of use of the composition.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 31/05 - Phenols
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61L 15/36 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing microorganisms
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Terpene-ensiched cannabinoid composition. Cannabinoid compositions are described including at least one cannabinoid in a specific amount, a primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene, carrier, optionally at least three secondary terpenes; less than 5% by weight glycol; and less than 20% by weight water, where said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said composition is about 0.1 to about 1.0. Also described are the above compositions where said non-cannabinoid, non-terpene carrier comprise less than 5% by weight cellulose and the terpenes to cannabinoids weight/weight ratio in said compositions is about 0.05 to about 1.0, forming terpene-enriched cannabinoid compositions with enhanced therapeutic effect compared with that of a composition comprising the same cannabinoids amounts and one half the amount of said primary terpene.

IPC Classes  ?

• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/01 - Hydrocarbons
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
• A61P 11/06 - Antiasthmatics
• A61P 25/22 - Anxiolytics
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/16 - Anti-Parkinson drugs
• A61P 35/00 - Antineoplastic agents
• A61K 31/05 - Phenols

Abstract

Provided is a liquid composition comprising a mixture of terpenes, at least one cannabinoid and an oil carrier. According to one embodiments, the mixture of terpenes comprises alpha-pinene, myrcene and caryophyllene and at least one additional terpene selected from the group consisting of limonene, terpinolene, linalool, geraniol, humulene, nerolidol, bisabolol and combinations thereof. According to a further embodiment, the mixture of terpenes comprises alpha-pinene, myrcene, caryophyllene, nerolidol and bisabolol, and at least one additional terpene selected from the group consisting of ocimene, limonene, linalool, and combinations thereof. According to a further embodiment, the mixture of terpenes comprises alpha-pinene, limonene, terpinolene and caryophyllene and optionally at least one additional terpene selected from the group consisting of beta-pinene, eucalyptol, geraniol and bisabolol, or combinations thereof.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/05 - Phenols
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/01 - Hydrocarbons
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates

Abstract

Provided are methods and compositions for reducing a throat irritation caused by inhaling vapors or particles of at least one material selected from the group consisting of cannabis, cannabinoids, tobaccO, a herb or combinations thereof, the method comprising administering to a subject in need thereof at least one transient receptor potential (TRP) channel modulator prior to or simultaneously with said inhaling said vapors or particles of said at least one material. Further provided are methods and compositions comprising at least one TRP channel agonist, and/or at least one TRP channel partial agonist for treating pain-selective analgesia via TRP channels; methods for treating local pain; methods for treating migraine and symptoms thereof; and methods for treating osteoporosis and symptoms thereof.

IPC Classes  ?

• A61K 31/05 - Phenols
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/365 - Lactones
• A61K 31/125 - CamphorNuclear substituted derivatives thereof
• A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61P 23/02 - Local anaesthetics
• A61K 31/11 - Aldehydes
• A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon

Abstract

Provided are methods for treating a bladder condition in a subject in need thereof by administering to said subject a therapeutically effective dose of a composition comprising at least one cannabinoid and a carrier. Also provided are cannabinoid composition comprising at least one cannabinoid, a carrier and at least one drug selected from the group consisting of an anticholinergic drug and an adrenergic drug and uses of such compositions for treating a bladder condition.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 13/10 - Drugs for disorders of the urinary system of the bladder
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Provided is a composition comprising an ester derived from at least one acid form of a cannabinoid (such as one selected from the group consisting of cannabigerolic acid (CBGA), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabichromenic acid (CBCA), cannabigerovarinic acid (CBGVA), tetrahydrocanabivarinic acid (CBCVA), cannabidivarinic acid (CBDVA) and cannabichromevarinic acid (CBCVA) and combinations thereof) and a water-soluble alkanol and uses thereof in therapy.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/05 - Phenols
• C07C 69/76 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring

Abstract

Pharmaceutical compositions having a carrier and a pharmaceutically effective amount of at least one modulator of an activity which is responsive to modulation by at least one selected from the group consisting of anadamide, N-Oleoylethanolamine (OEA), N-palmitoylethanolamind (PEA) and seretonine and is responsive to modulation by 2-arachidonoylglycerol (2-AG) to an extent that is no greater than that provided by at least one of anadamide, OEA, PEA and seretonine at the same molar dose, wherein the composition is devoid of a sole modulator selected from the group consisting of cannabidiol (CBD), anadamide N-Oleoylethanolamine (OEA), N-palmitoylethanolamind (PEA) and seretonine, for use in treating a condition characterized by anandamide deficiency or a symptom thereof, pharmaceutical preparations and kits including the composition, and methods of use thereof.

IPC Classes  ?

• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/05 - Phenols
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/01 - Hydrocarbons

Abstract

Provided is a kit comprising a first pharmaceutical composition comprising a first cannabinoid and optionally a first terpene and/or a first additive; and a second pharmaceutical composition comprising at least one selected from the group consisting of a second cannabinoid, a second terpene, a second additive and combinations thereof, and uses thereof in the treatment of pelvic pain arising from the female reproductive system. Further provided are methods of treatment of pelvic pain arising from a female reproductive system during a menstrual cycle, the method comprising administering during a first fraction of said menstrual cycle a first pharmaceutical composition comprising a first cannabinoid and optionally a first terpene and/or a first additive, and administering during a second fraction of said menstrual cycle a second pharmaceutical composition comprising at least one selected from the group consisting of a second cannabinoid, a second terpene, a second additive and combinations thereof.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/05 - Phenols
• A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/01 - Hydrocarbons
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 36/29 - Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
• A61K 36/88 - Liliopsida (monocotyledons)
• A61K 36/71 - Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
• A61K 36/8945 - Dioscorea, e.g. yam, Chinese yam or water yam
• A61K 36/65 - Paeoniaceae (Peony family), e.g. Chinese peony
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
• A61K 36/232 - Angelica
• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
• A61K 36/486 - Millettia
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Abstract

Provided is a solid homogeneous composition comprising at least one cannabinoid and a carrier having at least two of: (i) a total cannabinoid concentration greater than 5%; (ii) being in comminuted particle form, wherein at least 70 wt % of said particles are of size greater than 0.3 millimeter and less than 4.2 millimeters; (iii) comprising less than 20 wt % water; (iv) said carrier comprising cellulose; (v) said carrier comprises less than 50% by weight cannabis or hemp non-cannabinoid plant material, wherein said composition is suitable for providing cannabinoid via inhalation. Further provided are products comprising the composition, methods of use and methods of preparation thereof.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/05 - Phenols
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A24B 15/167 - Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
• A24B 15/28 - Treatment of tobacco products or tobacco substitutes by chemical substances

Abstract

Provided is a multi-users cannabis dispenser comprising: a vessel comprising at least two compartments, each compartment configured to contain at least one cannabis composition comprising at least one active component; at least one dispensing unit associated with said at least one compartment, said dispensing unit configured to controllably release from said compartments a metered dose of said composition contained therein; a control unit comprising a data input unit configured to receive data relating to a specific user, data indicating a metered dose of one or more said cannabis compositions to be administered to said specific user and/or to receive data relating to a specific cannabis composition, data indicating a metered dose of said specific composition to be administered to said specific user and configured to control the dispensing unit to release at least one said metered dose. Further provided are methods of use of the multi-users cannabis dispenser.

IPC Classes  ?

• A61M 15/00 - Inhalators
• A61K 31/05 - Phenols
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61M 11/04 - Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised

Abstract

Provided is a liquid composition comprising: at least one cannabinoid, wherein at least 50% by weight of said cannabinoid is in decarboxylated form; at least two volatile terpenes, each having a boiling point of less than 230ºC at atmospheric pressure; an oil-soluble carrier; and optionally, at least one non-volatile terpene having a boiling point of at least 230ºC at atmospheric pressure wherein a total volatile terpene to total cannabinoid weight/weight ratio is greater than 0.01:1.0; and wherein when said non-volatile terpene is present, the total volatile terpenes to total non-volatile terpenes weight/weight ratio is greater than 0.3:1.0. Further provided are methods of preparation thereof and methods of use thereof.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/24 - Antidepressants
• A61P 25/22 - Anxiolytics
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/20 - HypnoticsSedatives

Abstract

A terpene-enriched cannabinoid therapeutic product and methods for use thereof in treating conditions and/or symptoms associated with autism and/or autism spectrum disorder, the product including at least one cannabinoid, at least one primary terpene, and optionally at least three secondary terpenes, where the product has a therapeutic effect in treating conditions and/or symptoms associated with autism and/or autism spectrum disorder, and where said therapeutic effect is an enhanced therapeutic effect compared with that of a composition including the same cannabinoids amounts and one fifth the amount of said at least one primary terpene.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/4458 - Non-condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
• A61K 31/05 - Phenols
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 36/68 - Plantaginaceae (Plantain Family)
• A61K 36/23 - Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
• A61K 36/81 - Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
• A61K 36/41 - Crassulaceae (Stonecrop family)
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine

Abstract

A method of treatment including administering to a subject in need a therapeutically effective amount of a product having (i) at least one cannabinoid, (ii) at least one herbal preparation, where the herbal preparation is produced by at least one of distilling and extracting a portion of a plant, where the plant is not Cannabis sativa, (iii) at least one primary terpene selected from the group consisting of caryophyllene, linalool, pinene, eucalyptol, limonene, guaiol, geraniol, sabinene, terpineol, bisabolol, humulene, myrcene, nerolidol and combinations thereof, (iv) optionally at least three secondary terpenes, and (v) at least 5% by weight of a non-cannabinoid, non-terpene carrier.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/05 - Phenols
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61K 31/015 - Hydrocarbons carbocyclic

Abstract

A method of treatment comprising administering to a subject in need thereof a therapeutically effective amount of a product including (i) at least one isolated or synthetic cannabinoid, where at least a fraction of said isolated or synthetic cannabinoid is obtained by a process selected from the group consisting of processing hemp, chemical synthesis, biological synthesis, isolation from a plant source, crystallization and combinations thereof, (ii) optionally, at least one other cannabinoid, (iii) at least one primary terpene, and (iv) optionally at least three secondary terpenes.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/05 - Phenols
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/20 - HypnoticsSedatives
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Abstract

Provided is a method of treating a condition and/or a symptom in an animal, comprising administering to said animal (i) a therapeutically effective amount of at least one microorganism and/or of a prebiotic thereof, wherein said microorganism is capable of modulating an effect of at least one element of the endocannabinoid system of said animal and (ii) a therapeutically effective amount of at least one compound capable of modulating an effect of at least one element of the endocannabinoid system of said animals. Further provided are compositions for use in such methods.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics

Abstract

A cigarette containing a homogeneous composition including comminuted particles of dried Cannabis flowers, where the particles include a cannabinoid, the particles are of a size greater than 1.1 millimeter and less than 4.2 millimeter, the composition includes at least 9% and less than 20% by weight water, the composition has a bulk density greater than 0.08 and less than 0.3 gram/milliliter, and the cigarette has a top fraction and a bottom fraction, where when the top fraction and the bottom fraction are divided into 0.1 gram samples.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A24B 15/167 - Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
• A24C 5/02 - Cigarette-filling machines
• A24C 5/39 - Tobacco feeding devices
• A24D 1/02 - CigarsCigarettes with special covers
• A24D 1/18 - Selection of materials, other than tobacco, suitable for smoking
• A61K 36/185 - Magnoliopsida (dicotyledons)

Abstract

Provided is a liquid composition comprising at least one terpene (such as myrcene and caryophyllene; geraniol and at least one additional terpene; or alpha-pinene, myrcene, caryophyllene, nerolidol and bisabolol), at least one cannabinoid and an oil carrier, and uses thereof in therapy, such as treatment of pelvic pain, endometriosis, dysmenorrhea, muscle pain, muscle spasm, joint pain, arthritis, osteoarthrosis, abdominal pain, pain associated hormonal dysfunction, hormonal imbalance, hormonal changes, anxiety, stress, depression, irritability, lack of focus, lack of alertness, poor day function insomnia or sleep disorders.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/01 - Hydrocarbons
• A61K 31/05 - Phenols
• A61K 31/015 - Hydrocarbons carbocyclic

Abstract

Provided are pharmaceutical compositions comprising a pharmaceutically effective amount of a steroid and a pharmaceutically effective amount of at least one modulator selected from the group consisting of a transient receptor poteintial (TRP) channel modulator and a proliferatior-activated receptor (PRP) modulator, wherein cannabidiol is not present as the sole modulator, and uses thereof for treating a condition or a symptom thereof, wherein said condition involves inflammation, an immune disease, an autoimmune disease or a combination thereof.

IPC Classes  ?

• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 36/15 - Pinaceae (Pine family), e.g. pine or cedar
• A61K 36/18 - Magnoliophyta (angiosperms)
• A61K 36/25 - Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
• A61K 36/534 - Mentha (mint)
• A61K 36/63 - Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
• A61K 36/754 - Evodia
• A61K 33/24 - Heavy metalsCompounds thereof
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

Abstract

Provided is a method for treating conditions and/or symptoms associated therewith selected from the group consisting of androgen deficiency, male infertility, male urogenital or reproductive system infections and/or disorders and combinations thereof, comprising administering to a subject in need a therapeutically effective amount of a composition comprising at least one cannabinoid in a specific amount, at least one terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene carrier, and optionally at least one herbal extract, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and a weight/weight ratio of a total amount of terpenes to a total amount of cannabinoids is from about 0.1:1 to about 1:1, or; wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and a weight/weight ratio of a total amount of terpenes to a total amount cannabinoids is about 0.05:1 to about 1:1.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/01 - Hydrocarbons
• A61K 31/125 - CamphorNuclear substituted derivatives thereof
• A61K 31/05 - Phenols
• A61K 36/46 - Eucommiaceae (Eucommia family), e.g. hardy rubber tree
• A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 36/258 - Panax (ginseng)
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 36/19 - Acanthaceae (Acanthus family)
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 36/31 - Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
• A61K 33/30 - ZincCompounds thereof
• A61K 36/889 - Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61P 25/22 - Anxiolytics
• A61P 13/08 - Drugs for disorders of the urinary system of the prostate
• A61P 35/00 - Antineoplastic agents
• A61P 25/26 - Psychostimulants, e.g. nicotine, cocaine
• A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence
• A61P 25/24 - Antidepressants
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Provided is a pharmaceutical composition for treating a microbial imbalance, the composition comprising a pharmaceutically effective amount of at least one strain of probiotic bacteria, a pharmaceutically effective amount of cannabidiol and a pharmaceutically acceptable excipient. Further provided are feminine hygiene products comprising the composition and methods of use of the composition.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 35/741 - Probiotics
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Provided is a device suitable for direct topical administration of a pharmaceutical composition comprising at least one active component selected from the group consisting of cannabinoids, terpenes, flavonoids, CB1 receptor agonists, CB2 receptor agonists and combinations thereof to a region of the oral cavity of a subject and methods of use thereof. The device comprises a solid substrate having at least a portion configured and dimensioned to be contacted with the region of the oral cavity of the subject; and an amount of the pharmaceutical composition associated with at least a portion of the solid substrate, wherein the amount of pharmaceutical composition is at least partially releasable from the portion of solid substrate.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 8/34 - Alcohols
• A61K 31/05 - Phenols
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 8/31 - Hydrocarbons
• A61K 31/01 - Hydrocarbons
• A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 8/35 - Ketones, e.g. quinones, benzophenone
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 8/63 - SteroidsDerivatives thereof
• A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
• A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
• A61K 8/37 - Esters of carboxylic acids
• A61K 36/315 - Isatis, e.g. Dyer's woad
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 36/22 - Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
• A61K 36/537 - Salvia (sage)
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61K 36/71 - Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
• A61K 36/718 - Coptis (goldthread)
• A61K 36/58 - Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
• A61K 36/484 - Glycyrrhiza (licorice)
• A61K 36/328 - Commiphora, e.g. mecca myrrh or balm of Gilead
• A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form

Abstract

Provided are methods for treating conditions and/or symptoms selected from the group consisting of ulcer, viral infection, bacterial infection, fungal infection, infectious disease, and inflammation comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising at least one cannabinoid in a specific amount; at least one terpene in a specific amount, and at least 5% by weight of a non-cannabinoid, non-terpene carrier, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and a weight/weight ratio of a total amount of terpenes to a total amount of cannabinoids in said composition is from about 0.1:1 to about 1:1, or wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and a weight/weight ratio of a total amount of terpenes to a total amount cannabinoids in said composition is about 0.05:1 to about 1:1.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/05 - Phenols
• A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/01 - Hydrocarbons
• A61K 31/125 - CamphorNuclear substituted derivatives thereof
• A61K 31/11 - Aldehydes
• A61K 9/08 - Solutions
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies

Abstract

Provided are pharmaceutical compositions comprising a carrier and a pharmaceutically effective amount of at least one modulator of an activity which is responsive to modulation by at least one selected from the group consisting of anadamide, N-Oleoylethanolamine (OEA), N-palmitoylethanolamind (PEA) and seretonine and is responsive to modulation by 2-arachidonoylglycerol (2-AG) to an extent that is no greater than that provided by at least one of anadamide, OEA, PEA and seretonine at the same molar dose, wherein the composition is devoid of a sole modulator selected from the group consisting of cannabidiol (CBD), anadamide N-Oleoylethanolamine (OEA), N-palmitoylethanolamind (PEA) and seretonine, for use in treating a condition characterized by anandamide deficiency or a symptom thereof. Further disclosed are pharmaceutical preparations and kits comprising the composition, and methods of use thereof.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/01 - Hydrocarbons
• A61K 31/05 - Phenols
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 17/00 - Drugs for dermatological disorders
• A61P 25/06 - Antimigraine agents
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

An inhalation device is described, which inhalation device comprises an inlet for vapors and/or for aerosol, at least one terpene holding element configured to hold a selected terpene composition, and an outlet for vapors and/or for aerosol and wherein the device is configured to receive vapors and/or aerosol through the inlet, move the received vapors and/or aerosol through the device, infuse terpene composition into the moved vapors and/or aerosol and generate and emit terpene-enriched vapors and/or aerosol through the outlet, wherein at least one of the inlet, the holding element and the outlet is configured to limit the concentration of terpenes in the emitted terpenes-enriched vapors and/or aerosol to less than one percentage (by weight), when the moved vapors and/or aerosol is at 10 degrees Celsius and at atmospheric pressure.

IPC Classes  ?

• A61M 11/04 - Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
• A61M 15/06 - Inhaling appliances shaped like cigars, cigarettes or pipes
• A24F 40/30 - Devices using two or more structurally separated inhalable precursors, e.g. using two liquid precursors in two cartridges
• A24F 40/40 - Constructional details, e.g. connection of cartridges and battery parts
• A24F 40/57 - Temperature control
• A24F 40/10 - Devices using liquid inhalable precursors

Abstract

2.

IPC Classes  ?

• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 31/05 - Phenols

Abstract

Provided are methods and compositions for reducing a throat irritation caused by inhaling vapors or particles of at least one material selected from the group consisting of cannabis, cannabinoids, tobacc0, a herb or combinations thereof, the method comprising administering to a subject in need thereof at least one transient receptor potential (TRP) channel modulator prior to or simultaneously with said inhaling said vapors or particles of said at least one material. Further provided are methods and compositions comprising at least one TRP channel agonist, and/or at least one TRP channel partial agonist for treating pain-selective analgesia via TRP channels; methods for treating local pain; methods for treating migraine and symptoms thereof; and methods for treating osteoporosis and symptoms thereof.

IPC Classes  ?

• A61K 31/01 - Hydrocarbons
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/05 - Phenols
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A24B 15/28 - Treatment of tobacco products or tobacco substitutes by chemical substances
• A24B 15/30 - Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances

Abstract

Provided are methods for drying and sterilizing cannabis plant material comprising providing feed cannabis plant material having a water content of Mo, wherein Mo is greater than 45%; partially drying the feed cannabis plant material to form a partially dried cannabis plant material having a water content of M1, wherein M1 is in the range of between 12%wt and 40%wt; sterilizing the partially dried cannabis plant material to form sterilized partially dried cannabis plant material having a water content of M3; and when said M3 is less than 8% wt or greater than 16%wt, adjusting said M3 to provide a water content of M2, wherein said M2 is between 8%wt and 16%wt. Further provided are methods and systems for drying of cannabis plant material.

IPC Classes  ?

• F26B 9/06 - Machines or apparatus for drying solid materials or objects at rest or with only local agitationDomestic airing cupboards in stationary drums or chambers
• F26B 21/08 - Humidity
• F26B 3/00 - Drying solid materials or objects by processes involving the application of heat
• F26B 5/04 - Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
• A23L 3/005 - Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by heating using irradiation or electric treatment
• A23L 3/01 - Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by heating using irradiation or electric treatment using microwaves or dielectric heating
• A23L 3/16 - Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by heating loose unpacked materials
• A23L 3/26 - Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by irradiation without heating
• A23L 3/40 - Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
• A23N 12/08 - Machines for cleaning, blanching, drying or roasting fruits or vegetables, e.g. coffee, cocoa, nuts for drying or roasting
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline

Abstract

Provided is a solid homogeneous composition comprising at least one cannabinoid and a carrier having at least two of: (i) a total cannabinoid concentration greater than 5%; (ii) being in comminuted particle form, wherein at least 70 wt% of said particles are of size greater than 0.3 millimeter and less than 4.2 millimeters; (iii) comprising less than 20wt% water; (iv) said carrier comprising cellulose; (v) said carrier comprises less than 50% by weight cannabis or hemp non-cannabinoid plant material, wherein said composition is suitable for providing cannabinoid via inhalation. Further provided are products comprising the composition, methods of use and methods of preparation thereof.

IPC Classes  ?

• A61K 31/05 - Phenols
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/51 - Nanocapsules
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Provided is a therapeutic product comprising at least one cannabinoid; at least one primary terpene; and at least 5% by weight of a non-cannabinoid, non-terpene carrier, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said product is about 0.1 to about 1.0. Also provided is a method of treating certain conditions and/or symptoms in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a product comprising at least one primary terpene. Further provided is a therapeutic product comprising a primary terpene blend, wherein said primary terpene blend comprises five or less terpenes, and wherein each one of those terpenes, where present, independently comprises at least 10% of the total terpene content.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/05 - Phenols
• A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts

Abstract

Provided is a kit comprising a first pharmaceutical composition comprising a first cannabinoid and optionally a first terpene and/or a first additive; and a second pharmaceutical composition comprising at least one selected from the group consisting of a second cannabinoid, a second terpene, a second additive and combinations thereof, and uses thereof in the treatment of pelvic pain arising from the female reproductive system. Further provided are methods of treatment of pelvic pain arising from a female reproductive system during a menstrual cycle, the method comprising administering during a first fraction of said menstrual cycle a first pharmaceutical composition comprising a first cannabinoid and optionally a first terpene and/or a first additive, and administering during a second fraction of said menstrual cycle a second pharmaceutical composition comprising at least one selected from the group consisting of a second cannabinoid, a second terpene, a second additive and combinations thereof.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
• A61K 36/33 - Cactaceae (Cactus family), e.g. pricklypear or Cereus
• A61K 36/232 - Angelica
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

A product for treating conditions and/or symptoms associated with women health is described, which product comprises at least one cannabinoid in a specific amount, a primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene, carrier, optionally at least three secondary terpenes, and optionally at least one phytoestrogen; wherein said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said product is about 0.1 to about 1.0. Also described is the product wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight/weight ratio in said compositions is about 0.05 to about 1.0, forming a terpene-enriched product. Also described are uses of the product for treating conditions and/or symptoms associated with perimenopause, menopause, female urogenital or reproductive system infections and/or disorders, menstrual cycle, hormonal deficiency and/or hormonal imbalance.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 9/70 - Web, sheet or filament bases
• A61K 9/06 - OintmentsBases therefor
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies

Abstract

Provided is a terpene-enriched cannabinoid therapeutic product comprising at least one cannabinoid, at least one primary terpene, and optionally at least three secondary terpenes, wherein the product has a therapeutic effect in treating conditions and/ or symptoms associated with autism and/or autism spectrum disorder, and wherein said therapeutic effect is an enhanced therapeutic effect compared with that of a composition comprising the same cannabinoids amounts and one fifth the amount of said at least one primary terpene. Also provided are methods for use of the disclosed product in treating conditions and/or symptoms associated with autism and/or autism spectrum disorder.

IPC Classes  ?

• A61K 31/01 - Hydrocarbons
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/05 - Phenols
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Described is a therapeutic product comprising: at least one cannabinoid in a specific amount and at least one herbal preparation in a specific amount, wherein said herbal preparation is produced by at least one of distilling and extracting a portion of a plant, wherein said plant is not cannabis sativa. Also described are methods for using the product and methods for producing the product.

IPC Classes  ?

• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61K 31/05 - Phenols
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline

Abstract

A therapeutic product comprising (i) at least one selected cannabinoid in a specific amount, wherein at least a fraction of said selected cannabinoid is derived from processing hemp, chemical synthesis, biological synthesis, isolation from plant source and combination thereof, (ii) optionally, at least one other cannabinoid, (iii) a primary terpene in a specific amount, and (iv) optionally at least three secondary terpenes; forming a terpene-enriched cannabinoid product with an enhanced therapeutic effect compared with that of a product comprising the same cannabinoids amount and no terpene.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/01 - Hydrocarbons
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient

Abstract

Provided is a multi-users cannabis dispenser comprising: a vessel comprising at least two compartments, each compartment configured to contain at least one cannabis composition comprising at least one active component; at least one dispensing unit associated with said at least one compartment, said dispensing unit configured to controllably release from said compartments a metered dose of said composition contained therein; a control unit comprising a data input unit configured to receive data relating to a specific user, data indicating a metered dose of one or more said cannabis compositions to be administered to said specific user and/or to receive data relating to a specific cannabis composition, data indicating a metered dose of said specific composition to be administered to said specific user and configured to control the dispensing unit to release at least one said metered dose. Further provided are methods of use of the multi-users cannabis dispenser.

IPC Classes  ?

• A61M 15/00 - Inhalators
• A24F 9/00 - Accessories for smokers' pipes
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61M 16/10 - Preparation of respiratory gases or vapours

Abstract

A terpene-enriched composition for treating conditions and/or symptoms associated therewith in a male subject is described, which composition comprises at least one cannabinoid in a specific amount, a primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene, carrier, and optionally at least three secondary terpenes, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and a weight/weight ratio of a total amount of terpenes to a total amount of cannabinoids in said composition is from about 0.1:1 to about 1:1 or wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and a weight/weight ratio of a total amount of terpenes to a total amount of cannabinoids in said compositions is from about 0.05:1 to about 1:1. Conditions and/or symptoms associated therewith are selected from the group consisting of androgen deficiency, male infertility, male urogenital or reproductive system infections and/or disorders.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 31/04 - Antibacterial agents
• A61P 5/26 - Androgens
• A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• A61P 13/08 - Drugs for disorders of the urinary system of the prostate
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence

Abstract

Provided is a device suitable for direct topical administration of a pharmaceutical composition comprising at least one active component selected from the group consisting of cannabinoids, terpenes, flavonoids, CBi receptor agonists, CB2 receptor agonists and combinations thereof to a region of the oral cavity of a subject and methods of use thereof. The device comprises a solid substrate having at least a portion configured and dimensioned to be contacted with the region of the oral cavity of the subject; and an amount of the pharmaceutical composition associated with at least a portion of the solid substrate, wherein the amount of pharmaceutical composition is at least partially releasable from the portion of solid substrate.

IPC Classes  ?

• A42B 3/04 - Parts, details or accessories of helmets
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb

Abstract

Provided are cannabinoid compositions comprising at least one cannabinoid in a specific amount, at least one primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene, carrier, and optionally at least two secondary terpenes, where said non-cannabinoid, non-terpene carrier comprises cellulose and a weight/weight ratio of total terpenes to total cannabinoids in said composition is from about 0.1:1 to about 1:1. Also provided are methods for use of the disclosed compositions in treating conditions and/or symptoms associated with at least one of ulcer, viral infection, bacterial infection, fungal infection, infectious disease and inflammation.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)

Abstract

Provided are terpene-enriched cannabinoid composition. Cannabinoid compositions are described including at least one cannabinoid in a specific amount, at least one primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene, carrier, optionally at least two secondary terpenes; less than 5% by weight glycol; and less than 20% by weight water, where said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said composition is about 0.1 to about 1.0. Also described are the above compositions where said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight/weight ratio in said compositions is about 0.05:1 to about 1:1. The composition provides an enhanced therapeutic effect in treating conditions and/or symptoms associated with a stressful event, compared with that of a composition comprising the same cannabinoids amounts and one fifth the amount of said at least one primary terpene.

IPC Classes  ?

• A61K 31/01 - Hydrocarbons
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

An inhalation device is described, which inhalation device comprises an inlet for vapors and/or for aerosol, at least one terpene holding element configured to hold a selected terpene composition, and an outlet for vapors and/or for aerosol and wherein the device is configured to receive vapors and/or aerosol through the inlet, move the received vapors and/or aerosol through the device, infuse terpene composition into the moved vapors and/or aerosol and generate and emit terpene-enriched vapors and/or aerosol through the outlet, wherein at least one of the inlet, the holding element and the outlet is configured to limit the concentration of terpenes in the emitted terpenes-enriched vapors and/or aerosol to less than one percentage (by weight), when the moved vapors and/or aerosol is at 10 degrees Celsius and at atmospheric pressure.

IPC Classes  ?

• A61M 16/06 - Respiratory or anaesthetic masks

Abstract

12 22.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/05 - Phenols

Abstract

New cannabis compositions and industrial methods for production thereof. Homogeneous comminuted cannabis compositions comprising tetrahydrocannabinol and cannabidiol at selected weight/weight ratios, where at least 70 wt% of the comminuted cannabis plant material is of a size greater than 0.3 millimeter and less than 4.2 millimeters; the composition comprises at least 1wt% moisture and less than 20 wt% moisture; the tetrahydrocannabinol concentration in a 1 gram fraction of at least 10 gram sample of said homogeneous composition, is within 15% of the tetrahydrocannabinol concentration in a separate 1gram fraction of said 10 gram sample and the cannabidiol concentration in a 1 gram fraction of at least 10 gram sample of said homogeneous composition, is within 15% of the cannabidiol concentration in a separate 1gram fraction of said 10 gram sample.

IPC Classes  ?

• A61K 31/05 - Phenols
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 36/185 - Magnoliopsida (dicotyledons)

Abstract

New cannabis compositions and industrial methods for production thereof. Homogeneous comminuted cannabis compositions comprising tetrahydrocannabinol and cannabidiol at selected weight/weight ratios, where at least 70 wt% of the comminuted cannabis plant material is of a size greater than 0.3 millimeter and less than 4.2 millimeters; the composition comprises at least 1wt% moisture and less than 20 wt% moisture; the tetrahydrocannabinol concentration in a 1 gram fraction of at least 10 gram sample of said homogeneous composition, is within 15% of the tetrahydrocannabinol concentration in a separate 1gram fraction of said 10 gram sample and the cannabidiol concentration in a 1 gram fraction of at least 10 gram sample of said homogeneous composition, is within 15% of the cannabidiol concentration in a separate 1gram fraction of said 10 gram sample.

IPC Classes  ?

• A61K 31/05 - Phenols
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 36/185 - Magnoliopsida (dicotyledons)

Abstract

A therapeutic product comprising at least one cannabinoid in a specific amount, a primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non- terpene carrier, and optionally at least three secondary terpenes,; wherein said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said product is about 0.1 to about 1.0. Also described is the above product wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight/weight ratio in said compositions is about 0.05 to about 1.0, forming a terpene-enriched product with an enhanced therapeutic effect compared with that of a product comprising the same cannabinoids amounts and one half the amount of said primary terpene. compared with that of a product comprising the same cannabinoids amounts and one half the amount of said primary terpene.

IPC Classes  ?

• A61K 31/01 - Hydrocarbons
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/05 - Phenols
• A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline

Abstract

A therapeutic product comprising at least one cannabinoid in a specific amount, a primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non- terpene carrier, and optionally at least three secondary terpenes,; wherein said non- cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said product is about 0.1 to about 1.0. Also described is the above product wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight/weight ratio in said compositions is about 0.05 to about 1.0, forming a terpene-enriched product with an enhanced therapeutic effect compared with that of a product comprising the same cannabinoids amounts and one half the amount of said primary terpene. compared with that of a product comprising the same cannabinoids amounts and one half the amount of said primary terpene.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/05 - Phenols

Abstract

A product for treating conditions and/or symptoms associated with women health is described, which product comprises at least one cannabinoid in a specific amount, a primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene,carrier, optionally at least three secondary terpenes, and optionally at least one phytoestrogen; wherein said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said product is about 0.1 to about 1.0. Also described is the above product wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight/weight ratio in said compositions is about 0.05 to about 1.0, forming a terpene-enriched product with an enhanced therapeutic effect in treating conditions and/ or symptoms associated with perimenopause, menopause, female urogenital or reproductive system infections and/or disorders, menstrual cycle, hormonal deficiency and/or hormonal imbalance, compared with that of a product comprising the same cannabinoids amounts and one half the amount of said primary terpene.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

A product for treating conditions and/or symptoms associated with women health is described, which product comprises at least one cannabinoid in a specific amount, a primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene, carrier, optionally at least three secondary terpenes, and optionally at least one phytoestrogen; wherein said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said product is about 0.1 to about 1.0. Also described is the above product wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight/weight ratio in said compositions is about 0.05 to about 1.0, forming a terpene-enriched product with an enhanced therapeutic effect in treating conditions and/ or symptoms associated with perimenopause, menopause, female urogenital or reproductive system infections and/or disorders, menstrual cycle, hormonal deficiency and/or hormonal imbalance, compared with that of a product comprising the same cannabinoids amounts and one half the amount of said primary terpene.

IPC Classes  ?

• A61K 31/01 - Hydrocarbons
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

cannabis plant material a second composition comprising at least 10% of said cannabinoid and at least 1% of said terpene at cannabinoid to terpene weight/weight ratio R102, wherein R102 differs from R101 by at least 10%; and optionally refining said first composition, said second composition, or both.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/05 - Phenols

Abstract

Cannabis products and industrial methods for production thereof. A homogeneous composition comprising cannabinoid-containing comminuted cannabis plant material, where at least 70 weight% of the comminuted cannabis plant material is of a size greater than 0.3 millimeter and less than 4.2 millimeters; the composition comprises at least 1% by weight moisture and less than 20% by weight moisture; and the cannabinoid concentration in a 1 gram fraction of at least 10 gram sample of said homogeneous composition, is within 15% of the cannabinoid concentration in a separate 1 gram fraction of said 10 gram sample.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline

Abstract

Terpene-enriched cannabinoid composition. Cannabinoid compositions are described including at least one cannabinoid in a specific amount, a primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene, carrier, optionally at least three secondary terpenes; less than 5% by weight glycol; and less than 20% by weight water, where said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said composition is about 0.1 to about 1.0. Also described are the above compositions where said non-cannabinoid, non-terpene carrier comprise less than 5% by weight cellulose and the terpenes to cannabinoids weight/weight ratio in said compositions is about 0.05 to about 1.0, forming terpene-enriched cannabinoid compositions with enhanced therapeutic effect compared with that of a composition comprising the same cannabinoids amounts and one half the amount of said primary terpene.

IPC Classes  ?

• A61K 31/01 - Hydrocarbons
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

Terpene-enriched cannabinoid composition. Cannabinoid compositions are described including at least one cannabinoid in a specific amount, a primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene, carrier, optionally at least three secondary terpenes; less than 5% by weight glycol; and less than 20% by weight water, where said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said composition is about 0.1 to about 1.0. Also described are the above compositions where said non-cannabinoid, non-terpene carrier comprise less than 5% by weight cellulose and the terpenes to cannabinoids weight/weight ratio in said compositions is about 0.05 to about 1.0, forming terpene-enriched cannabinoid compositions with enhanced therapeutic effect compared with that of a composition comprising the same cannabinoids amounts and one half the amount of said primary terpene.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/01 - Hydrocarbons
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

Methods for the production of different cannabis product compositions. Method for the production of at least two different cannabis product compositions from a solid cannabis plant material are described including providing a solid cannabis plant material containing at least one cannabinoid and at least one terpene at cannabinoid to terpene weight/weight ratio R100; first extracting from said solid cannabis plant material a first composition comprising at least 10% but less than 90% of said cannabinoid and at least 1% of said terpene at cannabinoid to terpene weight/weight ratio R101, wherein R101 differs from R100 by at least 10%; second extracting from said solid cannabis plant material a second composition comprising at least 10% of said cannabinoid and at least 1% of said terpene at cannabinoid to terpene weight/weight ratio R102, wherein R102 differs from R101 by at least 10%; and optionally refining said first composition, said second composition, or both.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/01 - Hydrocarbons
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines